10.01.2013

Spinomix closes a USD3 Million financing round led by Debiopharm Group

Debiopharm, one of the most active investors in Switzerland last year, seems to be very active this year too. The group from Lausanne invests in Spinomix, a molecular diagnostics start-up.

Debiopharm Group and Spinomix SA, a Swiss company advancing molecular diagnostic technologies, announced the closing of a Series A equity investment of $ 3 Million. The financing round was led by Debiopharm Group. Significant participation and support is being provided by existing investors and a private US investor group with proven entrepreneurial experience. Debiopharm is a successful drug development company based in Switzerland which is active in the field of molecular diagnostics and has completed several equity rounds in diagnostic start-ups.
 
Spinomix focuses on delivering high-quality-low-cost solutions for sample preparation of biological materials. “This successful financing round is an important step in the company structure and technologies development plan. The funds allow Spinomix to consolidate its development pipeline and to strengthen existing and new IVD industry collaborations. Through our technologies we will expand on the industry sample processing methods and ultimately we aim to establish new diagnostic standards. The scaling-up of our organisation also demanded an expansion of our senior management”, says Lothar Wieczorek, Chairman of the board of directors.
 
Since Debiopharm was set up in 1979, the company and its founders have always focused on continuous innovation, while promoting entrepreneurship and the development of the Swiss high tech economy. Debiopharm believes that it is important to support entrepreneurs committed to innovation. “At a time where all healthcare players are expected to contribute to keeping healthcare cost under control, Debiopharm has been impressed by Spinomix platforms, their ease of use and huge potential for cost effective solutions”, says Thierry Mauvernay, Delegate of the Board, who adds “Debiopharm is extremely happy to become part of this entrepreneurial project”.
 
Spinomix SA is a life science company founded in 2004 and located at the Swiss Federal Institute of Technology of Lausanne (EPFL), Lausanne. The company was awarded the prize of the W. A. de Vigier Foundation in 2006 and the CTI Start-up label in 2009.

Industries

Biotech & Pharma

Categories

Capital, Investor

Highlights Spinomix

More news about Spinomix

Subscribe Newsletter


Stay up2date!

Get the startupticker.ch App
for your Phone or your Tablet!
   

Tickets for Swiss ICT Awards

The Swiss ICT Awards provides a very good networking opportunity. Participation is by invitation only and thanks to our partnership with Swiss ICT, we have received an allocation of tickets for start-ups. If interested, apply to news@startupticker.ch.

Partners

Sponsors